Fetal risks related to the treatment of multiple sclerosis during pregnancy and breastfeeding

Expert Review of Neurotherapeutics

Volumn 6, Issue 12, 2006, Pages 1823-1831

  Ferrero, Simone ^a   Esposito, Francesca ^a   Pretta, Stefano ^b   Ragni, Nicola ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Azathioprine; Cyclophosphamide; Glatiramer acetate; Glucocorticoids; Immunoglobulin; Interferon 1; Intravenous; Methotrexate; Mitoxantrone; Multiple sclerosis; Pregnancy

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; CORTISONE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GLATIRAMER; GLUCOCORTICOID; HYDROCORTISONE; IMMUNOGLOBULIN; INTERFERON; INTERFERON BETA SERINE; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB; PLACEBO; PREDNISONE;

ALOPECIA; ANENCEPHALUS; ASTHENOSPERMIA; BLEPHAROPHIMOSIS; BREAST FEEDING; CENTRAL NERVOUS SYSTEM MALFORMATION; CLEFT LIP; CLINICAL FEATURE; CLINICAL TRIAL; CONTRACEPTION; CRANIOFACIAL MALFORMATION; CRANIOFACIAL SYNOSTOSIS; DELIVERY; DIAGNOSTIC PROCEDURE; DISABILITY; DISEASE COURSE; DISEASE EXACERBATION; DOWN SYNDROME; DRUG MECHANISM; DRUG SAFETY; EAR MALFORMATION; EDEMA; FERTILITY; FETUS RISK; GROWTH RETARDATION; HEMORRHAGIC CYSTITIS; HUMAN; HYDROCEPHALUS; HYPERTENSION; INFECTION; INFERTILITY; INTRAUTERINE GROWTH RETARDATION; LIMB DEFECT; LOW BIRTH WEIGHT; MENINGOMYELOCELE; MENOPAUSE; MENSTRUATION; MONOTHERAPY; MULTIPLE SCLEROSIS; MUTAGENICITY; NAUSEA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPOROSIS; PATHOGENESIS; PREGNANCY; PREGNANCY DIABETES MELLITUS; PREGNANCY OUTCOME; PREMATURE FETUS MEMBRANE RUPTURE; PREMATURITY; RELAPSE; RESPIRATORY DISTRESS; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SODIUM RETENTION; SPONTANEOUS ABORTION; TERATOGENICITY; X CHROMOSOME ABERRATION;

BREAST FEEDING; FEMALE; FETAL DISEASES; HUMANS; IMMUNOLOGIC FACTORS; MATERNAL-FETAL EXCHANGE; MULTIPLE SCLEROSIS; PREGNANCY; RISK FACTORS;

EID: 33845906851     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.6.12.1823     Document Type: Review

References (79)

1. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46(4), 907-911 (1996).
2. Oksenberg JR, Barcellos LF. Multiple sclerosis genetics: leaving no stone unturned. Genes Immun. 6(5), 375-387 (2005).
3. Sadovnick AD, Armstrong H, Rice GP et al. A population-based study of multiple sclerosis in twins: update. Ann. Neurol. 33(3), 281-285 (1993).
4. Herrera BM, Ebers GC. Progress in deciphering the genetics of multiple sclerosis. Curr. Opin. Neurol. 16(3), 253-258 (2003).
5. Ebers GC, Sadovnick AD, Risch NJ. A genetic basis for familial aggregation in multiple sclerosis. Canadian Collaborative Study Group. Nature 377(6545), 150-151 (1995).
6. Robertson NP, Fraser M, Deans J, Clayton D, Walker N, Compston DA. Age-adjusted recurrence risks for relatives of patients with multiple sclerosis. Brain 119(Pt 2), 449-455 (1996).
7. Thacker EL, Mirzaei F, Ascherio A. Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. Ann. Neurol. 59(3), 499-503 (2006).
8. Perez-Cesari C, Saniger MM, Sotelo J. Frequent association of multiple sclerosis with varicella and zoster. Acta Neurol. Scand. 112(6), 417-419 (2005).
9. Christensen T. Association of human endogenous retroviruses with multiple sclerosis and possible interactions with herpes viruses. Rev. Med. Virol. 15(3), 179-211 (2005).
10. Sundstrom P, Juto P, Wadell G et al. An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study. Neurology 62(12), 2277-2282 (2004).
11. Thorogood M, Hannaford PC. The influence of oral contraceptives on the risk of multiple sclerosis. Br. J. Obstet. Gynaecol. 105(12), 1296-1299 (1998).
12. Hernan MA, Hohol MJ, Olek MJ, Spiegelman D, Ascherio A. Oral contraceptives and the incidence of multiple sclerosis. Neurology 55(6), 848-854 (2000).
13. Alonso A, Jick SS, Olek MJ, Ascherio A, Jick H, Hernan MA. Recent use of oral contraceptives and the risk of multiple sclerosis. Arch. Neurol. 62(9), 1362-1365 (2005).
14. Zorzon M, Zivadinov R, Bosco A et al. Sexual dysfunction in multiple sclerosis: a case-control study. I. Frequency and comparison of groups. Mult. Scler. 5(6), 418-427 (1999).
15. Schmidt EZ, Hofmann P, Niederwieser G, Kapfhammer HP, Bonelli RM. Sexuality in multiple sclerosis. J. Neural Transm. 112(9), 1201-1211 (2005).
16. Pretta S, Ferrero S, Ragni N (and MS-IVF Study Group). Ovulation induction and in vitro fertilization in women with multiple sclerosis. Proceedings of the 22nd Annual Meeting of the European Society of Human Reproduction and Embryology. Prague, Czech Republic. Hum. Reprod. 21(Suppl. 1), I145 (2006). • First study evaluating the effects of infertility treatments on the clinical course of multiple sclerosis (MS).
17. Runmarker B, Andersen O. Pregnancy is associated with a lower risk of onset and a better prognosis in multiple sclerosis. Brain 118(Pt 1), 253-261 (1995).
18. Grossman RI, Braffman BH, Brorson JR, Goldberg HI, Silberberg DH, Gonzalez-Scarano F. Multiple sclerosis: serial study of gadolinium-enhanced MR imaging. Radiology 169(1), 117-122 (1988).
19. Shellock FG, Kanal E. Safety of magnetic resonance imaging contrast agents. J. Magn. Reson. Imaging 10(3), 477-484 (1999).
20. Leyendecker JR, Gorengaut V, Brown JJ. MR imaging of maternal diseases of the abdomen and pelvis during pregnancy and the immediate postpartum period. Radiographics 24(5), 1301-1316 (2004).
21. Roullet E, Verdier-Taillefer MH, Amarenco P, Gharbi G, Alperovitch A, Marteau R. Pregnancy and multiple sclerosis: a longitudinal study of 125 remittent patients. J. Neurol. Neurosurg. Psychiatry 56(10), 1062-1065 (1993).
22. Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N. Engl. J. Med. 339(5), 285-291 (1998). • Large multicenter prospective study evaluating the rate of pregnancy-related relapse in MS.
23. Vukusic S, Hutchinson M, Hours M et al. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain 127(Pt 6), 1353-1360 (2004).
24. Vukusic S, Confavreux C. Pregnancy and multiple sclerosis: the children of PRIMS. Clin. Neurol. Neurosurg. 108(3), 266-270 (2006). •• Comprehensive review on the findings of the PRegnancy In Multiple Sclerosis (PRIMS) study.
25. Dahl J, Myhr KM, Daltveit AK, Hoff JM, Gilhus NE. Pregnancy, delivery, and birth outcome in women with multiple sclerosis. Neurology 65(12), 1961-1963 (2005). •• Nationwide historic cohort study evaluating the effects of maternal MS on pregnancy, delivery and birth outcome.
26. Dahl J, Myhr KM, Daltveit AK, Gilhus NE. Planned vaginal births in women with multiple sclerosis: delivery and birth outcome. Acta Neurol. Scand. 183, 51-54 (2006).
27. Weinshenker BG, Hader W, Carriere W, Baskerville J, Ebers GC. The influence of pregnancy on disability from multiple sclerosis: a population-based study in Middlesex County, Ontario. Neurology 39(11), 1438-1440 (1989).
28. Sloka JS, Stefanelli M. The mechanism of action of methylprednisolone in the treatment of multiple sclerosis. Mult. Scler. 11(4), 425-432 (2005).
29. Sellebjerg F, Barnes D, Filippini G et al. EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses. Eur. J. Neurol. 12(12), 939-946 (2005).
30. Park-Wyllie L, Mazzotta P, Pastuszak A et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 62(6), 385-392 (2000).
31. Panitch H, Miller A, Paty D, Weinshenker B. Interferon β-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 63(10), 1788-1795 (2004).
32. Jacobs L, Rudick R, Simon J. Extended observations on MS patients treated with IM interferon-β1a (Avonex): implications for modern MS trials and therapeutics. J. Neuroimmunol. 107(2), 167-173 (2000).
33. Piper JM, Wen TT, Xenakis EM. Interferon therapy in primary care. Prim. Care Update Ob. Gyns. 8(4), 163-169 (2001).
34. Arnason BG. Long-term experience with interferon β-1b (betaferon) in multiple sclerosis. J. Neurol. 252(Suppl. 3), 28-33 (2005).
35. Patti F, Pappalardo A, Florio C et al. Effects of interferon β-1a and -1b over time: 6-year results of an observational head-to-head study. Acta Neurol. Scand. 113(4), 241-247 (2006).
36. Koch-Henriksen N, Sorensen PS, Christensen T et al. A randomized study of two interferon-β treatments in relapsing-remitting multiple sclerosis. Neurology 66(7), 1056-1060 (2006).
37. Frohman EM, Racke MK, Raine CS. Multiple sclerosis - the plaque and its pathogenesis. N. Engl. J. Med. 354(9), 942-955 (2006).
38. Challier JC, Guerre-Millo M, Nandakumaran M, Gerbaut L, d'Athis P. Clearance of compounds of different molecular size in the human placenta in vitro. Biol. Neonate 48(3), 143-148 (1985).
39. Waysbort A, Giroux M, Mansat V, Teixeira M, Dumas JC, Puel J. Experimental study of transplacental passage of α interferon by two assay techniques. Antimicrob. Agents Chemother. 37(6), 1232-1237 (1993).
40. Pons JC, Lebon P, Frydman R, Delfraissy JF. Pharmacokinetics of interferon-α in pregnant women and fetoplacental passage. Fetal Diagn. Ther. 10(1), 7-10 (1995).
41. Biogen. Avonex® (Interferon β 1-a). Product monograph, 1998.
42. Sandberg-Wollheim M, Frank D, Goodwin TM et al. Pregnancy outcomes during treatment with interferon β-1a in patients with multiple sclerosis. Neurology 65(6), 802-806 (2005). •• Systematic and comprehensive analysis of pregnancy outcome after exposure to interferon (IFN)β-1a, the study was performed combining data from several randomized clinical trials.
43. Boskovic R, Wide R, Wolpin J, Bauer DJ, Koren G. The reproductive effects of β interferon therapy in pregnancy: a longitudinal cohort. Neurology 65(6), 807-811 (2005). • Small prospective study of pregnancy outcome after exposure to IFNβ-1a.
44. Munari L, Lovati R, Boiko A. Therapy with glatiramer acetate for multiple sclerosis. Cochrane Database Syst. Rev. 1, CD004678 (2004).
45. Farina C, Weber MS, Meinl E, Wekerle H, Hohlfeld R. Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action. Lancet Neurol. 4(9), 567-575 (2005).
46. Coyle PK, Johnson K, Pardo L, Stark Y. Pregnancy outcomes in patients with multiple sclerosis treated with glatiramer acetate (Copaxone1). Proceedings of the 55th Annual Meeting of the American Academy of Neurology Honolulu, Hawaii, USA. Neurology 60(5 Suppl. 1), A60 (2003). • First study evaluating pregnancy outcomes after exposure to glatiramer acetate.
47. Steinman L. Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nat. Rev. Drug Discov. 4(6), 510-518 (2005).
48. Polman CH, O'Connor PW, Havrdova E et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354(9), 899-910 (2006).
49. Gray O, McDonnell GV, Forbes RB. Methotrexate for multiple sclerosis. Cochrane Database Syst. Rev. 2:CD003208 (2004).
50. Kozlowski RD, Steinbrunner JV, MacKenzie AH, Clough JD, Wilke WS, Segal AM. Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. Am. J. Med. 88(6), 589-592 (1990).
51. Nguyen C, Duhl AJ, Escallon CS, Blakemore KJ. Multiple anomalies in a fetus exposed to low-dose methotrexate in the first trimester. Obstet. Gynecol. 99(4), 599-602 (2002).
52. Enns GM, Roeder E, Chan RT, Ali-Khan Catts Z, Cox VA, Golabi M. Apparent cyclophosphamide (cytoxan) embryopathy: a distinct phenotype? Am. J. Med. Genet. 86(3), 237-241 (1999).
53. Goodkin DE, Bailly RC, Teetzen ML, Hertsgaard D, Beatty WW. The efficacy of azathioprine in relapsing-remitting multiple sclerosis. Neurology 41(1), 20-55 (1991).
54. Lus G, Romano F, Scuotto A, Accardo C, Cotrufo R. Azathioprine and interferon β (1a) in relapsing-remitting multiple sclerosis patients: increasing efficacy of combined treatment. Eur. Neurol. 51(1), 15-20 (2004).
55. Pulicken M, Bash CN, Costello K et al. Optimization of the safety and efficacy of interferon β 1b and azathioprine combination therapy in multiple sclerosis. Mult. Scler. 11(2), 169-174 (2005).
56. Saarikoski S, Seppala M. Immunosuppression during pregnancy: transmission of azathioprine and its metabolites from the mother to the fetus. Am. J. Obstet. Gynecol. 115(8), 1100-1106 (1973).
57. Rosenkrantz JG, Githens JH, Cox SM, Kellum DL. Azathioprine (Imuran) and pregnancy. Am. J. Obstet. Gynecol. 97(3), 387-394 (1967).
58. Abu-Shakra M, Shoenfeld Y. Azathioprine therapy for patients with systemic lupus erythematosus. Lupus 10(3), 152-153 (2001).
59. Ferrero S, Ragni N. Inflammatory bowel disease: management issues during pregnancy. Arch. Gynecol. Obstet. 270(2), 79-85 (2004).
60. Radomski JS, Ahlswede BA, Jarrell BE et al. Outcomes of 500 pregnancies in 335 female kidney, liver, and heart transplant recipients. Transplant Proc. 27(1), 1089-1090 (1995).
61. Martinelli Boneschi F, Rovaris M, Capra R, Comi G. Mitoxantrone for multiple sclerosis. Cochrane Database Syst. Rev. 4:CD002127 (2005).
62. Hartung HP, Gonsette R, Konig N et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 360(9350), 2018-2025 (2002).
63. Cohen BA, Mikol DD. Mitoxantrone treatment of multiple sclerosis: safety considerations. Neurology 63(12 Suppl. 6), S28-S32 (2004).
64. Gonsette RE. Mitoxantrone in progressive multiple sclerosis: when and how to treat? J. Neurol. Sci. 206(2), 203-208 (2003)
65. Shenkenberg TD, Von Hoff DD. Possible mitoxantrone-induced amenorrhea. Cancer Treat. Rep. 70(5), 659-661 (1986).
66. Edan G, Brochet B, Clanet M et al. Safety profile of mitoxantrone in a cohort of 802 multiple sclerosis patients: a 4 year mean follow-up study. Proceedings of the 56th Annual Meeting of the American Academy of Neurology San Francisco, California, USA. Neurology 62(Suppl. 5), A493 (2004).
67. Lemez P, Urbanek V. Chemotherapy for acute myeloid leukemias with cytosine arabinoside, daunorubicin, etoposide, and mitoxantrone may cause permanent oligoasthenozoospermia or amenorrhea in middle-aged patients. Neoplasma 52(5), 398-401 (2005).
68. Goffette S, van Pesch V, Vanoverschelde JL, Morandini E, Sindic CJ. Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone. J. Neurol. 252(10), 1217-1222 (2005).
69. Ghalie RG, Edan G, Laurent M et al. Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology 59(6), 909-913 (2002).
70. Novoselac AV, Reddy S, Sanmugarajah J. Acute promyelocytic leukemia in a patient with multiple sclerosis following treatment with mitoxantrone. Leukemia 18(9), 1561-1562 (2004).
71. Voltz R, Starck M, Zingler V, Strupp M, Kolb HJ. Mitoxantrone therapy in multiple sclerosis and acute leukaemia: a case report out of 644 treated patients. Mult. Scler. 10(4), 472-474 (2004).
72. Gray O, McDonnell GV, Forbes RB. Intravenous immunoglobulins for multiple sclerosis. Cochrane Database Syst. Rev. 4:CD002936 (2003).
73. Rizvi SA, Bashir K. Other therapy options and future strategies for treating patients with multiple sclerosis. Neurology 63(12 Suppl. 6), S47-S54 (2004).
74. Achiron A, Rotstein Z, Noy S, Mashiach S, Dulitzky M, Achiron R. Intravenous immunoglobulin treatment in the prevention of childbirth-associated acute exacerbations in multiple sclerosis: a pilot study. J. Neurol. 243(1), 25-28 (1996).
75. Haas J. High dose IVIG in the post partum period for prevention of exacerbations in MS. Mult. Scler. 6(Suppl. 2), S18-S20 (2000).
76. Achiron A, Kishner I, Dolev M et al. Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis. J. Neurol. 251(9), 1133-1137 (2004). • Retrospective study evaluating the effectiveness of intravenous immunoglobulin administration to reduce the incidence of postpartum-related MS relapses.
77. Kumar AR, Hale TW, Mock RE. Transfer of interferon α into human breast milk. J. Hum. Lact. 16(3), 226-228 (2000).
78. Farrell R, Heaney D, Giovannoni G. Emerging therapies in multiple sclerosis. Expert Opin. Emerg. Drugs 10(4), 797-816 (2005).
79. Kappos L, Achtnichts L, Dahlke F et al. Genomics and proteomics: role in the management of multiple sclerosis. J. Neurol. 252(Suppl. 3), 21-27 (2005). •• Comprehensive review on pharmacogenetics, pharmacogenomics and proteomics in MS therapy.